Registered users only
Current Size: 100%
Registered users only
Travatan Z makes my vision so cloudy that I can hardly see. Cloudy is not really the word for it: it's more like the kind of vision you'd get from a combination of cataracts and a migraine headache.. What experience have others had with it?
The Pfizer MAINTAIN program helps eligible people in financial need continue to get their Pfizer medicines — including the glaucoma drug Xalatan® — if they have recently become unemployed and do not have prescription coverage. Beneficiaries of the program will get their Pfizer medicines for free for up to a year or until they become re-insured (whichever comes first).
Individuals and their immediate family members are eligible for this program if:
There was an interesting article on BBC today about recent advances in neuroprotection for glaucoma. Here are some highlights from the article:
Lead researcher Dr Stefano Bonini said: "Although neuroprotection in glaucoma has already been attempted with several compounds, this is the first time that an improvement in visual function is observed in patients with advanced optic nerve damage."
David Wright, chief executive of the International Glaucoma Association, warned against drawing firm conclusions from such a small study - but said the results were encouraging.
He said: "There have been many false dawns in the search for neuro-protective agents for the treatment of glaucoma and it is a feature of research on other compounds that early promise does not always translate into clinical effectiveness when larger studies are undertaken.
"However, this research would seem to indicate both effectiveness and acceptability as to the means of drug delivery.
"If these early indications are carried through to wider trials and there are no other problems, then this has the potential to open a completely new method of treating glaucoma and of preventing unnecessary visual loss in the future."
The combination drug bimatoprost/timolol (marketed as Ganfort®) comprises the synthetic prostamide bimatoprost and the β-adrenergic receptor antagonist timolol.
A hydrogen sulphide-releasing derivative of latanoprost acid (ACS 67) was synthesized and tested in vivo to evaluate its activity on reduction of intraocular pressure and tolerability. Glutathione (GSH) and cGMP content were also measured in the aqueous humour. The increased reduction of intraocular pressure, with a marked increase of GSH and cGMP and the related potential neuroprotective properties, make this compound interesting for the treatment of glaucoma.
Correct instillation of eye drops is crucial for successful treatment of eye disease. Many patients have difficulties instilling eye drops, especially patients with loss of fixation, who cannot see the tip of the bottle. These patients may turn to harmful techniques, such as touching the dropper tip to the eye, or wasteful ones, such as feeling the sensation of drops hitting the eye or lower lid.1 Non-compliance may become an issue as well, resulting from a combination of poor drop administration and frustration. The frustration stems from an inability to see the bottle tip.
We describe a new method of drop instillation which increases the accuracy with which eye drops are dispensed, thereby decreasing the incidence of harmful techniques, and possibly increasing compliance.
What's in the bottle on the right in the photo below?
Nearly four weeks ago I wrote the blog post about my intraocular pressure reaching a record low of 6.7 mmHg as measured by the Reichert Ocular Response Analyzer.